Renovaro Past Earnings Performance
Past criteria checks 0/6
Renovaro's earnings have been declining at an average annual rate of -36.9%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-36.9%
Earnings growth rate
-29.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -94.6% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Enochian stock climbs on US patent for oncology platform
Oct 17Enochian BioSciences discovers two sets of altered animal data in two of its studies
Jul 01Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?
Jun 28Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Feb 20Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Oct 30Enochian Biosciences: A Follow Through For An HIV Cure
Jun 26Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment
Jun 14Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?
Feb 14Revenue & Expenses BreakdownBeta
How Renovaro makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -41 | 19 | 2 |
30 Sep 23 | 0 | -41 | 19 | 2 |
30 Jun 23 | 0 | -40 | 15 | 4 |
31 Mar 23 | 0 | -107 | 16 | 5 |
31 Dec 22 | 0 | -109 | 15 | 6 |
30 Sep 22 | 0 | -111 | 14 | 8 |
30 Jun 22 | 0 | -113 | 14 | 8 |
31 Mar 22 | 0 | -41 | 13 | 19 |
31 Dec 21 | 0 | -38 | 12 | 19 |
30 Sep 21 | 0 | -35 | 10 | 18 |
30 Jun 21 | 0 | -27 | 8 | 16 |
31 Mar 21 | 0 | -13 | 7 | 5 |
31 Dec 20 | 0 | -11 | 7 | 6 |
30 Sep 20 | 0 | -10 | 7 | 5 |
30 Jun 20 | 0 | -11 | 7 | 5 |
31 Mar 20 | 0 | -6 | 7 | 4 |
31 Dec 19 | 0 | -7 | 8 | 2 |
30 Sep 19 | 0 | -22 | 9 | 3 |
30 Jun 19 | 0 | -18 | 8 | 2 |
31 Mar 19 | 0 | -21 | 8 | 2 |
31 Dec 18 | 0 | -21 | 8 | 2 |
30 Sep 18 | 0 | -6 | 6 | 1 |
30 Jun 18 | 0 | -6 | 5 | 1 |
31 Mar 18 | 0 | -4 | 4 | 1 |
Quality Earnings: RENB is currently unprofitable.
Growing Profit Margin: RENB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RENB is unprofitable, and losses have increased over the past 5 years at a rate of 36.9% per year.
Accelerating Growth: Unable to compare RENB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RENB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: RENB has a negative Return on Equity (-94.58%), as it is currently unprofitable.